Want to see SE:IMMU full AI Analyst Report?

Immunicum AB (IMMU) Price & Analysis

3 Followers

IMMU Stock Chart & Stats

kr5.77

kr0.08(1.09%)

At close: Mar 06 4:00 PM EST

kr5.77

kr0.08(1.09%)

Day’s Range― - ―

52-Week Rangekr3.86 - kr8.49

Previous CloseN/A

Volume3.78K

Average Volume (3M)20.02K

Market Cap

kr348.89M

Enterprise Valuekr322.08M

Total Cash (Recent Filing)kr59.88M

Total Debt (Recent Filing)kr17.93M

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Nov 11, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.79

Shares Outstanding64,784,580

10 Day Avg. Volume23,864

30 Day Avg. Volume20,020

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.46

Revenue Forecast (FY)kr5.00M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low leverage gives Immunicum greater financial flexibility than many early-stage biotech companies. Limited debt reduces interest and refinancing pressure, allowing more of its available capital to support clinical development and other strategic priorities.

Narrowing LossesNarrower losses indicate some improvement in cost absorption and operating performance relative to the two prior reported periods. If maintained, this trend could extend the company’s funding runway and reduce the pace at which equity is consumed.

Improved Cash Burn Versus 2023The material improvement in cash burn from 2023 suggests spending discipline has strengthened over time. While this does not yet create self-funding operations, a lower burn rate can preserve liquidity longer and provide more time for development progress.

Bears Say

No Recurring Revenue BaseZero revenue across the latest TTM and two annual periods leaves the company without a consistent commercial funding base. Operations therefore remain dependent on external financing or collaboration-related payments rather than repeatable product sales.

Persistent UnprofitabilityPersistent operating and net losses show that the current business does not yet cover its cost structure. Continued unprofitability can require additional funding, constrain investment choices, and increase the importance of successful clinical and commercial development.

Ongoing Cash BurnConsistently negative operating and free cash flow means Immunicum is not generating the cash needed to fund operations internally. This creates continuing reliance on financing or other capital sources and leaves less financial resilience if development spending persists.

IMMU FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was kr3.86 and its highest was kr8.49 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is kr348.89M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Nov 11, 2026 which is in 11 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on Aug 20, 2026. The company reported -kr0.34 earnings per share for the quarter, beating the consensus estimate of -kr0.45 by kr0.11.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate is -0.48.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 64,784,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -kr0.34 in its last earnings report, beating expectations of -kr0.45. Following the earnings report the stock price went down -0.149%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in SE:IMMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.